1
|
Gutti G, Leifeld J, Kakarla R, Bajad NG, Ganeshpurkar A, Kumar A, Krishnamurthy S, Klein-Schmidt C, Tapken D, Hollmann M, Singh SK. Discovery of triazole-bridged aryl adamantane analogs as an intriguing class of multifunctional agents for treatment of Alzheimer's disease. Eur J Med Chem 2023; 259:115670. [PMID: 37515920 DOI: 10.1016/j.ejmech.2023.115670] [Citation(s) in RCA: 5] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/02/2023] [Revised: 07/10/2023] [Accepted: 07/19/2023] [Indexed: 07/31/2023]
Abstract
Alzheimer's disease (AD) is a progressive brain disorder associated with slow loss of brain functions leading to memory failure and modest changes in behavior. The multifactorial neuropathological condition is due to a depletion of cholinergic neurons and accumulation of amyloid-beta (Aβ) plaques. Recently, a multi-target-directed ligand (MTDL) strategy has emerged as a robust drug discovery tool to overcome current challenges. In this research work, we aimed to design and develop a library of triazole-bridged aryl adamantane analogs for the treatment of AD. All synthesized analogs were characterized and evaluated through various in vitro and in vivo biological studies. The optimal compounds 32 and 33 exhibited potent inhibitory activities against acetylcholinesterase (AChE) (32 - IC50 = 0.086 μM; 33 - 0.135 μM), and significant Aβ aggregation inhibition (20 μM). N-methyl-d-aspartate (NMDA) receptor (GluN1-1b/GluN2B subunit combination) antagonistic activity of compounds 32 and 33 measured upon heterologous expression in Xenopus laevis oocytes showed IC50 values of 3.00 μM and 2.86 μM, respectively. The compounds possessed good blood-brain barrier permeability in the PAMPA assay and were safe for SH-SY5Y neuroblastoma (10 μM) and HEK-293 cell lines (30 μM). Furthermore, in vivo behavioral studies in rats demonstrated that both compounds improved cognitive and spatial memory impairment at a dose of 10 mg/kg oral administration. Together, our findings suggest triazole-bridged aryl adamantane as a promising new scaffold for the development of anti-Alzheimer's drugs.
Collapse
Affiliation(s)
- Gopichand Gutti
- Department of Pharmaceutical Engineering & Technology, Indian Institute of Technology (Banaras Hindu University), Varanasi, 221005, India; Department of Biochemistry I - Receptor Biochemistry, Faculty of Chemistry and Biochemistry, Ruhr University Bochum, Bochum, Germany
| | - Jennifer Leifeld
- Department of Biochemistry I - Receptor Biochemistry, Faculty of Chemistry and Biochemistry, Ruhr University Bochum, Bochum, Germany
| | - Ramakrishna Kakarla
- Department of Pharmaceutical Engineering & Technology, Indian Institute of Technology (Banaras Hindu University), Varanasi, 221005, India
| | - Nilesh Gajanan Bajad
- Department of Pharmaceutical Engineering & Technology, Indian Institute of Technology (Banaras Hindu University), Varanasi, 221005, India
| | - Ankit Ganeshpurkar
- Department of Pharmaceutical Engineering & Technology, Indian Institute of Technology (Banaras Hindu University), Varanasi, 221005, India
| | - Ashok Kumar
- Department of Pharmaceutical Engineering & Technology, Indian Institute of Technology (Banaras Hindu University), Varanasi, 221005, India
| | - Sairam Krishnamurthy
- Department of Pharmaceutical Engineering & Technology, Indian Institute of Technology (Banaras Hindu University), Varanasi, 221005, India
| | - Christina Klein-Schmidt
- Department of Biochemistry I - Receptor Biochemistry, Faculty of Chemistry and Biochemistry, Ruhr University Bochum, Bochum, Germany
| | - Daniel Tapken
- Department of Biochemistry I - Receptor Biochemistry, Faculty of Chemistry and Biochemistry, Ruhr University Bochum, Bochum, Germany
| | - Michael Hollmann
- Department of Biochemistry I - Receptor Biochemistry, Faculty of Chemistry and Biochemistry, Ruhr University Bochum, Bochum, Germany
| | - Sushil Kumar Singh
- Department of Pharmaceutical Engineering & Technology, Indian Institute of Technology (Banaras Hindu University), Varanasi, 221005, India.
| |
Collapse
|
2
|
Khan SA, Akhtar MJ, Gogoi U, Meenakshi DU, Das A. An Overview of 1,2,3-triazole-Containing Hybrids and Their Potential Anticholinesterase Activities. Pharmaceuticals (Basel) 2023; 16:179. [PMID: 37259329 PMCID: PMC9961747 DOI: 10.3390/ph16020179] [Citation(s) in RCA: 12] [Impact Index Per Article: 12.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/31/2022] [Revised: 01/18/2023] [Accepted: 01/22/2023] [Indexed: 07/30/2023] Open
Abstract
Acetylcholine (ACh) neurotransmitter of the cholinergic system in the brain is involved in learning, memory, stress responses, and cognitive functioning. It is hydrolyzed into choline and acetic acid by two key cholinesterase enzymes, viz., acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE). A loss or degeneration of cholinergic neurons that leads to a reduction in ACh levels is considered a significant contributing factor in the development of neurodegenerative diseases (NDs) such as Alzheimer's disease (AD). Numerous studies have shown that cholinesterase inhibitors can raise the level of ACh and, therefore, enhance people's quality of life, and, at the very least, it can temporarily lessen the symptoms of NDs. 1,2,3-triazole, a five-membered heterocyclic ring, is a privileged moiety, that is, a central scaffold, and is capable of interacting with a variety of receptors and enzymes to exhibit a broad range of important biological activities. Recently, it has been clubbed with other pharmacophoric fragments/molecules in hope of obtaining potent and selective AChE and/or BuChE inhibitors. The present updated review succinctly summarizes the different synthetic strategies used to synthesize the 1,2,3-triazole moiety. It also highlights the anticholinesterase potential of various 1,2,3-triazole di/trihybrids reported in the past seven years (2015-2022), including a rationale for hybridization and with an emphasis on their structural features for the development and optimization of cholinesterase inhibitors to treat NDs.
Collapse
Affiliation(s)
- Shah Alam Khan
- College of Pharmacy, National University of Science and Technology, Muscat 130, Oman
| | | | - Urvashee Gogoi
- Department of Pharmaceutical Sciences, Dibrugarh University, Dibrugarh 786004, India
| | | | - Aparoop Das
- Department of Pharmaceutical Sciences, Dibrugarh University, Dibrugarh 786004, India
| |
Collapse
|
3
|
Ouach A, Vercouillie J, Bertrand E, Rodrigues N, Pin F, Serriere S, Boiaryna L, Chartier A, Percina N, Tangpong P, Gulhan Z, Mothes C, Deloye JB, Guilloteau D, Page G, Suzenet F, Buron F, Chalon S, Routier S. Bis(het)aryl-1,2,3-triazole quinuclidines as α7 nicotinic acetylcholine receptor ligands: Synthesis, structure affinity relationships, agonism activity, [18F]-radiolabeling and PET study in rats. Eur J Med Chem 2019; 179:449-469. [DOI: 10.1016/j.ejmech.2019.06.049] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/29/2019] [Revised: 06/16/2019] [Accepted: 06/17/2019] [Indexed: 12/12/2022]
|
4
|
Jain A, Piplani P. Exploring the Chemistry and Therapeutic Potential of Triazoles: A Comprehensive Literature Review. Mini Rev Med Chem 2019; 19:1298-1368. [DOI: 10.2174/1389557519666190312162601] [Citation(s) in RCA: 26] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/01/2018] [Revised: 02/28/2019] [Accepted: 03/06/2019] [Indexed: 12/20/2022]
Abstract
:
Triazole is a valuable platform in medicinal chemistry, possessing assorted pharmacological
properties, which could play a major role in the common mechanisms associated with various disorders
like cancer, infections, inflammation, convulsions, oxidative stress and neurodegeneration. Structural
modification of this scaffold could be helpful in the generation of new therapeutically useful
agents. Although research endeavors are moving towards the growth of synthetic analogs of triazole,
there is still a lot of scope to achieve drug discovery break-through in this area. Upcoming therapeutic
prospective of this moiety has captured the attention of medicinal chemists to synthesize novel triazole
derivatives. The authors amalgamated the chemistry, synthetic strategies and detailed pharmacological
activities of the triazole nucleus in the present review. Information regarding the marketed triazole derivatives
has also been incorporated. The objective of the review is to provide insights to designing and
synthesizing novel triazole derivatives with advanced and unexplored pharmacological implications.
Collapse
Affiliation(s)
- Ankit Jain
- Department of Pharmaceutical Chemistry, University Institute of Pharmaceutical Sciences, Panjab University, Chandigarh- 160014, India
| | - Poonam Piplani
- Department of Pharmaceutical Chemistry, University Institute of Pharmaceutical Sciences, Panjab University, Chandigarh- 160014, India
| |
Collapse
|
5
|
Wang W, Wang W, Yao G, Ren Q, Wang D, Wang Z, Liu P, Gao P, Zhang Y, Wang S, Song S. Novel sarsasapogenin-triazolyl hybrids as potential anti-Alzheimer's agents: Design, synthesis and biological evaluation. Eur J Med Chem 2018; 151:351-362. [DOI: 10.1016/j.ejmech.2018.03.082] [Citation(s) in RCA: 24] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/03/2017] [Revised: 03/24/2018] [Accepted: 03/30/2018] [Indexed: 12/22/2022]
|
6
|
Fu DJ, Song J, Zhao RH, Liu YC, Zhang YB, Liu HM. Synthesis of Novel Antiproliferative 1,2,3-triazole Hybrids Using the Molecular Hybridisation Approach. JOURNAL OF CHEMICAL RESEARCH 2016. [DOI: 10.3184/174751916x14761050193688] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
A series of nine novel 1,2,3-triazole-chalcone derivatives were designed using the molecular hybridisation approach and synthesised by click chemistry. Most of the synthesised compounds exhibited moderate to good antiproliferative activity against oesophagus, gastric and neuroendocrine cancer cell lines, but a compound containing a p-bromo group in the A ring and a [(4,5-dihydrothiazol-2-yl)thio]methyl group attached at the 4-position of a p-[3-(1,2,3-triazol-1-yl)propyloxy] group in the B ring showed the highest activity with an IC50 value of 8.16 μM against neuroendocrine cancer cells. The structure activity relationships of all nine compounds were discussed.
Collapse
Affiliation(s)
- Dong-Jun Fu
- Collaborative Innovation Center of New Drug Research and Safety Evaluation, School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001, P.R. China
| | - Jian Song
- Collaborative Innovation Center of New Drug Research and Safety Evaluation, School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001, P.R. China
| | - Ruo-Han Zhao
- Collaborative Innovation Center of New Drug Research and Safety Evaluation, School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001, P.R. China
| | - Ying-Chao Liu
- Collaborative Innovation Center of New Drug Research and Safety Evaluation, School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001, P.R. China
| | - Yan-Bing Zhang
- Collaborative Innovation Center of New Drug Research and Safety Evaluation, School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001, P.R. China
| | - Hong-Min Liu
- Collaborative Innovation Center of New Drug Research and Safety Evaluation, School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001, P.R. China
| |
Collapse
|
7
|
Sarasamkan J, Scheunemann M, Apaijai N, Palee S, Parichatikanond W, Arunrungvichian K, Fischer S, Chattipakorn S, Deuther-Conrad W, Schüürmann G, Brust P, Vajragupta O. Varying Chirality Across Nicotinic Acetylcholine Receptor Subtypes: Selective Binding of Quinuclidine Triazole Compounds. ACS Med Chem Lett 2016; 7:890-895. [PMID: 27774124 DOI: 10.1021/acsmedchemlett.6b00146] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/07/2016] [Accepted: 08/09/2016] [Indexed: 12/16/2022] Open
Abstract
The novel quinuclidine anti-1,2,3-triazole derivatives T1-T6 were designed based on the structure of QND8. The binding studies revealed that the stereochemistry at the C3 position of the quinuclidine scaffold plays an important role in the nAChR subtype selectivity. Whereas the (R)-enantiomers are selective to α7 over α4β2 (by factors of 44-225) and to a smaller degree over α3β4 (3-33), their (S)-counterparts prefer α3β4 over α4β2 (62-237) as well as over α7 (5-294). The (R)-derivatives were highly selective to α7 over α3β4 subtypes compared to (RS)- and (R)-QND8. The (S)-enantiomers are 5-10 times more selective to α4β2 than their (R) forms. The overall strongest affinity is observed for the (S)-enantiomer binding to α3β4 (Ki, 2.25-19.5 nM) followed by their (R)-counterpart binding to α7 (Ki, 22.5-117 nM), with a significantly weaker (S)-enantiomer binding to α4β2 (Ki, 414-1980 nM) still above the very weak respective (R)-analogue affinity (Ki, 5059-10436 nM).
Collapse
Affiliation(s)
- Jiradanai Sarasamkan
- Center
of Excellence for Innovation in Drug Design and Discovery, Faculty
of Pharmacy, Mahidol University, 447 Sri-Ayutthaya Road, Bangkok 10400, Thailand
- Department
of Neuroradiopharmaceuticals, Institute of Radiopharmaceutical
Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf, Permoserstraße15, 04318 Leipzig, Germany
- National
Cyclotron and PET Centre, Chulabhorn Hospital, 54 Kamphaengphet 6 Road, Bangkok 10210, Thailand
| | - Matthias Scheunemann
- Department
of Neuroradiopharmaceuticals, Institute of Radiopharmaceutical
Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf, Permoserstraße15, 04318 Leipzig, Germany
| | - Nattayaporn Apaijai
- Neurophysiology
Unit, Cardiac Electrophysiology Research and Training Center, Faculty
of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand
| | - Siripong Palee
- Neurophysiology
Unit, Cardiac Electrophysiology Research and Training Center, Faculty
of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand
| | - Warisara Parichatikanond
- Department
of Pharmacology, Faculty of Pharmacy, Mahidol University, 447 Sri-Ayutthaya
Road, Bangkok 10400, Thailand
| | - Kuntarat Arunrungvichian
- Center
of Excellence for Innovation in Drug Design and Discovery, Faculty
of Pharmacy, Mahidol University, 447 Sri-Ayutthaya Road, Bangkok 10400, Thailand
| | - Steffen Fischer
- Department
of Neuroradiopharmaceuticals, Institute of Radiopharmaceutical
Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf, Permoserstraße15, 04318 Leipzig, Germany
| | - Siriporn Chattipakorn
- Neurophysiology
Unit, Cardiac Electrophysiology Research and Training Center, Faculty
of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand
| | - Winnie Deuther-Conrad
- Department
of Neuroradiopharmaceuticals, Institute of Radiopharmaceutical
Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf, Permoserstraße15, 04318 Leipzig, Germany
| | - Gerrit Schüürmann
- Department
of Ecological Chemistry, Helmholtz Centre for Environmental Research−UFZ, Permoserstraße15, 04318 Leipzig, Germany
- Institute
for Organic Chemistry, Technical University Bergakademie Freiberg, Leipziger Straße29, 09596 Freiberg, Germany
| | - Peter Brust
- Department
of Neuroradiopharmaceuticals, Institute of Radiopharmaceutical
Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf, Permoserstraße15, 04318 Leipzig, Germany
| | - Opa Vajragupta
- Center
of Excellence for Innovation in Drug Design and Discovery, Faculty
of Pharmacy, Mahidol University, 447 Sri-Ayutthaya Road, Bangkok 10400, Thailand
| |
Collapse
|
8
|
Bürgi JJ, Bertrand S, Marger F, Bertrand D, Reymond J. Fluorescent Agonists of the
α
7 Nicotinic Acetylcholine Receptor Derived from 3‐Amino‐Quinuclidine. Helv Chim Acta 2016. [DOI: 10.1002/hlca.201600120] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- Justus J. Bürgi
- Department of Chemistry and Biochemistry University of Berne Freiestrasse 3 CH‐3012 Berne
| | - Sonia Bertrand
- HiQScreen Sàrl 6 route de Compois CH‐1222 Vésenaz Geneva
| | - Fabrice Marger
- HiQScreen Sàrl 6 route de Compois CH‐1222 Vésenaz Geneva
| | | | - Jean‐Louis Reymond
- Department of Chemistry and Biochemistry University of Berne Freiestrasse 3 CH‐3012 Berne
| |
Collapse
|
9
|
Reyes-Parada M, Iturriaga-Vasquez P. The development of novel polypharmacological agents targeting the multiple binding sites of nicotinic acetylcholine receptors. Expert Opin Drug Discov 2016; 11:969-81. [DOI: 10.1080/17460441.2016.1227317] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
|